Skip to main content

ADVERTISEMENT

Poster

Both Transcranial Magnetic Stimulation (TMS) and Esketamine are FDA approved therapies for patients with Major Depressive Disorder who have failed at least one conventional antidepressant...
10/26/2023
This analysis evaluated changes in functioning and productivity in patients with treatment resistant depression who received either esketamine nasal spray or quetiapine extended release, ...
10/26/2023
This post hoc analysis explored the efficacy of brexpiprazole 2 or 3 mg/day in patients with agitation associated with Alzheimer’s dementia, based on presence or absence of psychosis at b...
10/26/2023
Depression is a prevalent comorbidity associated with migraine. In patients with migraine and major depressive disorder, treatment with fremanezumab was associated with significant reduct...
10/26/2023
Adult patients with acute or stable schizophrenia received RBP-7000 (a once-monthly subcutaneous extended-release risperidone formulation) in two Phase III studies (8-week inpatient doubl...
10/26/2023
This post hoc, pooled analysis of 3 short-term, placebo-controlled studies evaluated the efficacy of once-daily lumateperone 42mg monotherapy and adjunctive therapy in patients experienci...
10/26/2023
A systematic review and meta-analysis exploring the magnitude of emotion dysregulation in individuals with various diagnosed psychiatric conditions compared to healthy individuals. Using ...
10/26/2023
Detailed study designs for the EMPOWER program will be presented. Primary outcome measure for EMPOWER 1 and 2 is change from baseline in PANSS total score at week 6. Other outcome measure...
10/26/2023
Challenges to accessing affordable and high-quality mental health care persist amidst significantly rising demand. This study explored the use of telemedicine technology among PAs practic...
10/26/2023
In a double-blind, randomized, parallel-group, active- and placebo-controlled, 14-day, dose-finding study in adult/elderly subjects with insomnia disorder, the 10 mg and 20 mg dose groups...
10/26/2023